AbCellera Biologics and Eli Lilly and Co. said they will work together to develop antibody products that can be used to prevent and treat COVID-19, the disease caused by the novel coronavirus, and their goal is to start testing in patients within the next four months. Biogen also agreed to collaborate with Vir Biotechnology to advance the development of Vir's human monoclonal antibodies as potential therapies for COVID-19.
Drugmakers race to develop COVID-19 treatments
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.